Transport of topoisomerase I inhibitors by the breast cancer resistance protein: Potential clinical implications

Annals of the New York Academy of Sciences

Volumn 922, Issue , 2000, Pages 188-194

  Schellens, Jan H M ^a,b,c   Maliepaard, Marc ^a   Scheper, Rik J ^b   Scheffer, George L ^a   Jonker, Johan W ^b   Smit, Johan W ^c   Beijnen, Jos H ^a   Schinkel, Alfred H ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; GLYCOPROTEIN P; IRINOTECAN; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BXP34; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG; VERAPAMIL;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CELL CULTURE; CANCER RESISTANCE; CONFERENCE PAPER; CONTROLLED STUDY; CROSS RESISTANCE; DRUG ACCUMULATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; OVARY CANCER; PROTEIN LOCALIZATION;

EID: 0034508219     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb07037.x     Document Type: Conference Paper

References (25)

1. Mechanism of multidrug resistance
2. Biochemistry of multidrug resistance mediated by the multidrug transporter
3. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
4. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK16
5. Cellular localization of the multidrug resistance gene product in normal human tissue
6. The physiological function of drug-transporting P-glycoproteins
7. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
8. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833
9. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A
10. Co-administration of cyclosporin enables oral therapy with paclitaxel
11. Co-administration of cyclosporin enables oral therapy with paclitaxel
12. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance
13. Multidrug resistance in human tumors - Molecular diagnosis and clinical significance
14. Modulation of multidrug resistance (MDR) in hematological malignancies
15. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats
16. A multidrug resistance transporter from MCF-7 breast cancer cells
17. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines
18. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes
19. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance
20. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line
21. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms in human plasma
22. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines
23. The mouse Bcrp1/Mxr/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin
24. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR
25. Bioavailability and pharmacokinetics of oral topotecan, a new topoisomerase I inhibitor